➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Dow
McKesson

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 4,014,991

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,014,991
Title: Oral rabies immunization of carnivores
Abstract:A vaccine and method of protecting wild carnivores and especially foxes from rabies virus which comprises setting out and orally administering an immunizing dose of an attenuated liquid antirabies vaccine, said vaccine being enclosed in a bite-permeable hydrophobic plastic container or sheath and said container being surrounded by an acceptable meat bait for the carnivore such as cured sausage. An elongated shape for both the container and bait is preferred. Acceptable vaccines for utilization include ERA/BHK-21 and PRI virus and a plastic elongated polyethylene tube is preferred for the container holding the attenuated vaccine. An effective amount of a temperature stabilizer for the vaccine may be added for operating temperatures of 27.degree..sup.+C. and these temperature stabilizers are selected from purified casein hydrolysates. The present method operates by bite penetration of the plastic container so that the vaccine is transferred to the buccal mucosa of the carnivore and the present method is effective in the treatment of wild carnivores, especially foxes.
Inventor(s): Baer; George M. (Stone Mountain, GA), Winkler; William G. (Stone Mountain, GA)
Assignee: The United States of America as represented by the Department of Health, (Washington, DC)
Application Number:05/651,810
Patent Claims:see list of patent claims

Details for Patent 4,014,991

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Biologicals Sa RABAVERT rabies vaccine KIT 103334 1 2016-12-19   Start Trial The United States of America as represented by the Department of Health, (Washington, DC) 2040-01-28 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Dow
Express Scripts
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.